Therefore, we tested 2 FDA-approved DNMTi, azacitidine (AZA) and decitabine (DAC), in the pediatric high-grade glioma cell line, PBT-05FHTC, which expresses relatively low baseline levels of MHC I. Interferon-gamma (IFNɣ) was used as a positive control. Here, IFNA1 is linked to glioma.